Clinical Trials

LymphoidMyeloidOther hematologic neoplasmPlasma cell

80 enrolled

Hodgkin Disease, Leukemia, Plasma Cell, Multiple Myeloma, Myelodysplastic Syndromes, Neoplasms, Germ Cell and Embryonal, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Lymphoma, B-Cell

NCT06207123 2026-03-18

A Study to Investigate LP-118, Ponatinib, Vincristine and Dexamethasone in Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL)

15 enrolled

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06634589 2026-03-18

A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies

80 enrolled

Neoplasms, Recurrence, Lymphoma, B-Cell

NCT07069699 2026-03-18

Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene

50 enrolled

Burkitt Lymphoma

NCT07155226 2026-03-18

MOMENTUM

LymphoidMyeloidOther hematologic neoplasm

84 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05909527 2026-03-17

A Clinical Study of CAR-T Treating Relapsed or Refractory T Cell Lymphoblastic Acute Leukemia/ Lymphoma

Phase 1/2 Withdrawn

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT02332668 2026-03-16

MK-3475-051

370 enrolled

DermatologicLymphoid

Lymphoma, Melanoma

NCT03590574 2026-03-16

Phase I/II Study Evaluating AUTO4 in Patients With T Cell Receptor Beta Constant (TRBC)1 Positive T Cell Lymphoma

Phase 1/2 Terminated

20 enrolled 34 charts

Immunoblastic Lymphadenopathy, Lymphoma, T-Cell, Lymphoma, Large-Cell, Anaplastic

NCT04588922 2026-03-16

Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML

160 enrolled

Lymphoma, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute, Hematologic Neoplasms

NCT06481735 2026-03-16

TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-ALL

30 enrolled

Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06561425 2026-03-16

Atalanta-1

130 enrolled

Burkitt Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT07473167 2026-03-16

TC011

98 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT03523975 2026-03-13

Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma

28 enrolled

Lymphoma, Mantle-Cell

NCT05421663 2026-03-13

A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma

439 enrolled

Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

NCT07471789 2026-03-13

Safety and Efficacy of GYA01 (CART84) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Acute Lymphoblastic T Leukemia Patients (T-ALL).

33 enrolled

Leukemia, T-Cell, Leukemia, Myeloid, Acute, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT02392572 2026-03-12

ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome

LymphoidMyeloidOther hematologic neoplasm

120 enrolled

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05442515 2026-03-12

CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies

126 enrolled

Burkitt Lymphoma, Lymphoma, Lymphoma, Non-Hodgkin, Philadelphia Chromosome, Leukemia, B-Cell, Lymphoma, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07284433 2026-03-12

QUADvance

178 enrolled

Leukemia, Lymphoma, Lymphoma, Large B-Cell, Diffuse

NCT02213913 2026-03-11

Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas

Phase 1/2 Completed

55 enrolled 17 charts

Hodgkin Disease, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Intraocular Lymphoma

NCT06395103 2026-03-11

MK-9999-01A

90 enrolled

CNSLymphoidSarcoma

Burkitt Lymphoma, Neuroblastoma, Sarcoma, Ewing, Lymphoma, Large B-Cell, Diffuse

NCT05256641 2026-03-10

Acalabrutinib Maintenance for the Treatment of Patients With Large B-cell Lymphoma

24 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT06316856 2026-03-10

CD5 Chimeric Antigen Receptor (CAR) T Cells in Subjects With Relapsed or Refractory T-cell Malignancies

54 enrolled

Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT03681561 2026-03-09

Nivolumab With Ruxolitinib in Relapsed or Refractory Classical Hodgkin Lymphoma

54 enrolled

Hodgkin Disease

NCT04521231 2026-03-06

A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL

281 enrolled

Phase 1/2 Not yet recruiting

Recurrence, Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07225985 2026-03-06

Pralatrexate With Bendamustine and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma

50 enrolled

Lymphoma, T-Cell

NCT03075696 2026-03-05

A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma

940 enrolled 1 FDA

Lymphoma, Non-Hodgkin

NCT05475925 2026-03-05

A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas

DermatologicLymphoidOther hematologic neoplasm

69 enrolled

Subcutaneous panniculitis-like T-cell lymphoma, Leukemia, Lymphoma, Leukemia, Large Granular Lymphocytic, Lymphoma, Extranodal NK-T-Cell, Enteropathy-Associated T-Cell Lymphoma

NCT07222631 2026-03-05

SB-4826 in Adult Participants With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphomas

48 enrolled

Lymphoma, Non-Hodgkin

NCT03331198 2026-03-04

Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

320 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04416984 2026-03-04

ALPHA2

160 enrolled

Leukemia, Lymphoma, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT04623541 2026-03-04

EPCORE™ CLL-1

195 enrolled

GenitourinaryHead & NeckLymphoid

Leukemia, Lymphocytic, Chronic, B-Cell

NCT05721222 2026-03-04

Trial of PRO1160 (GEN1160) in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) (PRO1160-001)

Phase 1/2 Terminated

42 enrolled

Nasopharyngeal Carcinoma, Carcinoma, Renal Cell, Lymphoma, Non-Hodgkin

NCT07109219 2026-03-04

ALLight

83 enrolled

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07294677 2026-03-04

CAVALRY

104 enrolled

Leukemia, Lymphoma

NCT03625037 2026-03-03

EPCORE™ NHL-1

666 enrolled 2 FDA

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Marginal Zone

NCT04542824 2026-03-03

EPCORE™ NHL-3

78 enrolled

Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone

NCT04663347 2026-03-03

EPCORE™ NHL-2

543 enrolled

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse

NCT05546268 2026-03-03

Study of Oral MRT-2359 in Selected Cancer Patients

BreastGenitourinaryLymphoidThoracic

174 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Prostatic Neoplasms, Lymphoma, Large B-Cell, Diffuse, Small Cell Lung Carcinoma

NCT05950165 2026-03-03

A Study to Assess Safety and Efficacy of CHO-H01 as a Single Agent/Combined With Lenalidomide in Subjects With Refractory or Relapsed Non-Hodgkin's Lymphoma

37 enrolled

Lymphoma, Follicular, Lymphoma, Non-Hodgkin

NCT07249905 2026-03-03

Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma

180 enrolled

LymphoidSarcoma

Lymphoma, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Lymphoma, B-Cell, Marginal Zone, Dendritic Cell Sarcoma, Interdigitating

NCT07302347 2026-03-03

MK-3475-G21

20 enrolled

DermatologicLymphoid

Lymphoma, Neoplasms, Carcinoma, Merkel Cell

NCT04077723 2026-03-02

A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

498 enrolled

Lymphoma, Non-Hodgkin

NCT06364423 2026-03-02

Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Leukemias

132 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05702853 2026-02-27

Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL

27 enrolled

Phase 1/2 Not yet recruiting

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell

NCT07439653 2026-02-27

A Study of TORL-5-700 in Relapsed/Refractory Non Hodgkin's Lymphoma

155 enrolled

Lymphoma, B-Cell

NCT03504644 2026-02-25

Venetoclax and Vincristine in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia

40 enrolled 18 charts

Burkitt Lymphoma, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT06052813 2026-02-25

A Study of BN104 in the Treatment of Acute Leukemia

66 enrolled

Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT04851119 2026-02-24

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors